
RANI Stock Forecast & Price Target
RANI Analyst Ratings
Bulls say
Rani Therapeutics Holdings Inc has demonstrated successful delivery of PG-102 via oral administration with enhanced bioavailability, marking a significant advancement in the development of its RaniPill technology. The partnership with Chugai not only validates the RaniPill platform but also positions the company within a lucrative multi-billion dollar market for biologics, suggesting growth potential through strategic collaborations. Additionally, with a robust cash runway extending through 2028, Rani is well-equipped to advance its programs, potentially unlocking substantial value for shareholders while being at the forefront of innovations in oral drug delivery solutions.
Bears say
Rani Therapeutics Holdings Inc faces a negative outlook primarily due to uncertainty surrounding its revenue forecasts, which are heavily dependent on achieving specific reimbursement levels; any failure to meet these expectations could adversely impact financial projections. Additionally, there are concerns related to competition that may disrupt Rani's pipeline and future product candidates, further complicating revenue generation. While the company has demonstrated mechanical safety through an extensive dataset, the potential for failure in future clinical trials remains a significant risk to its financial viability and market valuations.
This aggregate rating is based on analysts' research of Rani Therapeutics Holdings and is not a guaranteed prediction by Public.com or investment advice.
RANI Analyst Forecast & Price Prediction
Start investing in RANI
Order type
Buy in
Order amount
Est. shares
0 shares